New pill targets Hard-to-Treat cancers with RAS mutations

NCT ID NCT05379985

Recruiting now Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take the drug by mouth, and researchers will monitor their health closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RMC-6236 (oral tablet)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced cancers that have specific RAS mutations, especially those who haven't responded to other therapies.
What could go wrong: This is a very early (Phase 1/2) trial, so the drug may not work or could have serious side effects. It's also only for people with certain genetic mutations, so it won't help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm digestive system neoplasm intestinal cancer lung neoplasm melanoma neoplasm Neoplasm Metastasis Neoplastic Processes non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS COLORECTAL CANCER (CRC) NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Christ Hospital Cancer Center
RECRUITING

Cincinnati, Ohio, 45219, United States
Columbia University
RECRUITING

New York, New York, 10032, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
Mary Bird Perkins Cancer Center
RECRUITING

Baton Rouge, Louisiana, 70809, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Memorial Sloan-Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Next Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Next Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Piedmont Healthcare
RECRUITING

Atlanta, Georgia, 30318, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
Tennessee Oncology
RECRUITING

Chattanooga, Tennessee, 37404, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UC Irvine/Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
UCLA
RECRUITING

Santa Monica, California, 90404, United States
University of Texas at Austin
RECRUITING

Austin, Texas, 78712, United States
Virginia Mason Medical Center
RECRUITING

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.